VistaGen Therapeutics
VTGN
25 hedge funds and large institutions have $7.99M invested in VistaGen Therapeutics in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 7 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
71% more capital invested
Capital invested by funds: $4.68M → $7.99M (+$3.31M)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
19% more funds holding
Funds holding: 21 → 25 (+4)
0.15% more ownership
Funds ownership: 0.33% → 0.49% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.89M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$797K |
| 3 |
PVI
Pura Vida Investments
New York
|
+$618K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$565K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$525K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
-$270K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$39K |
| 3 |
Millennium Management
New York
|
-$28K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| 5 |
CPA
Cowen Prime Advisors
New York
|
-$4K |
VTGN Hedge Fund Activity: Q1 2019 in Review
25 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2019, worth a combined $7.99M — up 71% from $4.68M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new VTGN positions and 7 closed out — a net gain of 4 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.89M. The largest seller was Ibex Investors, exiting entirely with an estimated $270K sold.
- 25 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2019, up from 21 in Q4 2018.
- Funds reported $7.99M of VistaGen Therapeutics stock for Q1 2019, up 71% quarter-over-quarter.
- 11 funds opened new VistaGen Therapeutics positions in Q1 2019 and 7 closed out, a net change of +4 holders.
- The largest VistaGen Therapeutics buyer in Q1 2019 was Point72 Asset Management, an estimated $1.89M added.
- The largest VistaGen Therapeutics seller in Q1 2019 was Ibex Investors, an estimated $270K sold.
Based on aggregated 13F filings for Q1 2019.